SG11201808628PA - Array-based peptide libraries for therapeutic antibody characterization - Google Patents

Array-based peptide libraries for therapeutic antibody characterization

Info

Publication number
SG11201808628PA
SG11201808628PA SG11201808628PA SG11201808628PA SG11201808628PA SG 11201808628P A SG11201808628P A SG 11201808628PA SG 11201808628P A SG11201808628P A SG 11201808628PA SG 11201808628P A SG11201808628P A SG 11201808628PA SG 11201808628P A SG11201808628P A SG 11201808628PA
Authority
SG
Singapore
Prior art keywords
international
rule
target proteins
c4ob
arizona
Prior art date
Application number
SG11201808628PA
Inventor
Matthew Greving
David Smith
Gaurav Saini
Original Assignee
Healthtell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healthtell Inc filed Critical Healthtell Inc
Publication of SG11201808628PA publication Critical patent/SG11201808628PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • C40B50/18—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support using a particular method of attachment to the solid support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623—Immobilisation or binding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00675—In-situ synthesis on the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709—Type of synthesis
    • B01J2219/00711—Light-directed synthesis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Structural Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111 0111010101111101111111101111111111111101111111111111111111111111110111111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/173365 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, G01N 33/543 (2006.01) C40B 50/14 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, G01N 33/68 (2006.01) C4OB 50/18 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C4OB 40/10 (2006.01) CO8F 118/02 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, C4OB 30/04 (2006.01) HO1J 49/16 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (21) International Application Number: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, PCT/US2017/025546 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (22) International Filing Date: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 31 March 2017 (31.03.2017) ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/317,353 1 April 2016 (01.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/472,504 16 March 2017 (16.03.2017) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: HEALTHTELL INC. [US/US]; 2420 Camino SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Ramon, Suite 125, San Ramon, California 94583 (US). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors: GREYING, Matthew; 8829 S. 51st Street, #1, Declarations under Rule 4.17: Phoenix, Arizona 85044 (US). SMITH, David; 10485 N. — as to applicant's entitlement to apply for and be a granted 97th Place, Scottsdale, Arizona 85258 (US). SAINI, patent (Rule 4. / 7(H)) Gaurav; 900 N. Rural Road, Apt. 1093, Chandler, Arizona — 85226 (US). as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) (74) Agents: BONNEFOUS, Celine et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, Published: California 94304 (US). — with international search report (Art. 21(3)) Designated States indicated, (81) (unless otherwise for every kind of national protection available): AE, AG, AL, AM, [Continued on next page] = (54) Title: ARRAY-BASED PEPTIDE LIBRARIES FOR THERAPEUTIC ANTIBODY CHARACTERIZATION Mask 1 Mask 2 Mask 3 ,0 %Iw,, N A ''4 , % •V *•h • : % • „ „ w‘ : %% % •,N • • • , :„„::4h.N: •: ,-, Feature Overlap: 1 &2 2&3 1 &2&3 kr) M IN FIG. 6 IN 1-1 IN 1-1 (57) : Provided herein are methods, chemical library and simulation system for performing in situ patterned chemistry. 0 Methods, systems and assays comprising the use of the synthesized chemical libraries, which increase explored protein space in a \" knowledge-based manner, are also provided for characterizing antibody-target interactions including: identifying target proteins of C antibodies, characterizing antibody-binding regions in target proteins, identifying linear and structural epitopes in target proteins, and determining the propensity of antibody binding to target proteins. WO 2017/173365 Al MIDEDIMOHNOIIMME301011111110iMEHEVOIMIE — before the expiration of the time limit for amending the claims and amendments (Rule to be republished 48.2(h)) in the event of receipt of
SG11201808628PA 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization SG11201808628PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317353P 2016-04-01 2016-04-01
US201762472504P 2017-03-16 2017-03-16
PCT/US2017/025546 WO2017173365A1 (en) 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization

Publications (1)

Publication Number Publication Date
SG11201808628PA true SG11201808628PA (en) 2018-10-30

Family

ID=59966524

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808628PA SG11201808628PA (en) 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization

Country Status (9)

Country Link
US (3) US20190113522A1 (en)
EP (1) EP3436825A4 (en)
JP (1) JP2019520421A (en)
KR (1) KR20180136464A (en)
CN (2) CN109313184A (en)
AU (1) AU2017240164A1 (en)
CA (1) CA3019596A1 (en)
SG (1) SG11201808628PA (en)
WO (1) WO2017173365A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430574A1 (en) 2009-04-30 2012-03-21 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
JP2019536860A (en) 2016-11-09 2019-12-19 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． Coating with adjustable amine specific gravity
WO2019074940A1 (en) * 2017-10-09 2019-04-18 Healthtell Inc. Integrated platform for target and specificity information-derived binding partner selection
WO2019074934A1 (en) * 2017-10-09 2019-04-18 Healthtell Inc. Immunogens for directed immune response and antibodies therefrom
EP3749676A4 (en) * 2018-02-09 2021-12-22 Healthtell Inc. Array-based cyclic peptide libraries
US11894139B1 (en) 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
KR100529600B1 (en) * 2003-01-23 2005-11-22 정만길 Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them
EP3138855A1 (en) * 2005-02-23 2017-03-08 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
MX358281B (en) * 2012-07-04 2018-08-13 Hoffmann La Roche Covalently linked antigen-antibody conjugates.
WO2014062981A1 (en) * 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
KR102160389B1 (en) * 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 De novo synthesized gene libraries
US20170212101A1 (en) * 2014-07-18 2017-07-27 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties

Also Published As

Publication number Publication date
US20240159770A1 (en) 2024-05-16
US20190113522A1 (en) 2019-04-18
CA3019596A1 (en) 2017-10-05
AU2017240164A1 (en) 2018-11-15
EP3436825A1 (en) 2019-02-06
EP3436825A4 (en) 2020-03-18
CN115094523A (en) 2022-09-23
KR20180136464A (en) 2018-12-24
CN109313184A (en) 2019-02-05
JP2019520421A (en) 2019-07-18
WO2017173365A1 (en) 2017-10-05
US20240077492A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
SG11201808628PA (en) Array-based peptide libraries for therapeutic antibody characterization
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201808196UA (en) Neoantigens and methods of their use
SG11201808261RA (en) Genetic variant-phenotype analysis system and methods of use
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201811025VA (en) Systems and methods for automated annotation and screening of biological sequences
SG11201809649WA (en) Macromolecule analysis employing nucleic acid encoding
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201806190TA (en) Isotachophoresis for purification of nucleic acids